Hematological Toxicity of Combined ¹⁷⁷Lu-Octreotate Radiopeptide Chemotherapy of Gastroenteropancreatic Neuroendocrine Tumors in Long-Term Follow-Up

Publisher： Karger

E-ISSN： 1423-0194|99|2|108-117

ISSN： 0028-3835

Source： Neuroendocrinology, Vol.99, Iss.2, 2014-04, pp. : 108-117

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination ¹⁷⁷Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy

Neuroendocrinology, Vol. 103, Iss. 5, 2015-06 ,pp. : 432-439

Karger

Access to resources Recommend Favorite

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Follow-Up and Documentation

Neuroendocrinology, Vol. 90, Iss. 2, 2009-08 ,pp. : 227-233

Karger

Access to resources Recommend Favorite

Ectopic Intrathyroidal Thymus in Children: A Long-Term Follow-Up Study

Hormone Research in Paediatrics, Vol. 75, Iss. 4, 2010-12 ,pp. : 258-263

Karger

Access to resources Recommend Favorite

Treatment with the Radiolabelled Somatostatin Analog ¹⁷⁷Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

Neuroendocrinology, Vol. 97, Iss. 4, 2013-05 ,pp. : 347-354

Karger

Access to resources Recommend Favorite

Epigenetic Aspects on Therapy Development for Gastroenteropancreatic Neuroendocrine Tumors

Neuroendocrinology, Vol. 97, Iss. 1, 2012-03 ,pp. : 19-25

Karger

Access to resources Recommend Favorite